Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 16/20 | 0.45 |
| ▸ | F10 | P00742 | 16/20 | 0.45 |
| ▸ | F2 | P00734 | 15/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 15/20 | 0.45 |
| ▸ | F3 | P13726 | 8/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5882097 | 0.90 | F7 (0.46) | F7F10F2PRSS1F3 | |
| SCHEMBL5882374 | 0.87 | F7 (0.43) | F7F10F2PRSS1F3 | |
| SCHEMBL5883882 | 0.83 | F7 (0.47) | F7F10F2PRSS1F3 | |
| SCHEMBL5883524 | 0.82 | F7 (0.42) | F7F10F2PRSS1F3 | |
| SCHEMBL5883068 | 0.82 | F10 (0.42) | F7F10F2PRSS1F3 | |
| SCHEMBL5882582 | 0.78 | MRGPRX1 (0.38) | F7F10F2PRSS1F3 | |
| SCHEMBL6869365 | 0.75 | F7 (0.47) | F7F10F2PRSS1F3 | |
| SCHEMBL5883227 | 0.75 | F7 (0.46) | F7F10F2PRSS1F3 | |
| SCHEMBL5882852 | 0.75 | F7 (0.43) | F7F10F2PRSS1F3 | |
| SCHEMBL5882875 | 0.75 | F7 (0.44) | F7F10F2PRSS1F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071212-B2 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1149069-B1 | PHENYLGLYCINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2004-02-19 | — | — | US | disclosed |
| US-6683215-B2 | TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION AND ARTERIOSCLEROSIS, WHICH ARE ASSOCIATED WITH COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA AND TISSUE FACTOR; ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2003-05-01 | — | — | US | disclosed |
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | F7 1019/4885F10 520/4885F2 371/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | F7 1019/4885F10 520/4885F2 371/4885 |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | F7 1019/4885F10 520/4885F2 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.